Barbeau A, Roy M
Neurology. 1976 May;26(5):399-404. doi: 10.1212/wnl.26.5.399.
A combination of levodopa and a peripheral dopa-decarboxylase inhibitor, benzerazide (Ro 4-4602), was studied over a 75-month period of observation in 132 patients with Parkinson's disease. The combined therapeutic approach was without biological toxicity, was well tolerated by 95 percent of patients, and was highly effective: 72 percent of patients improved by more than 50 percent on a functional activity scale and the group as a whole improved on an objective battery by a mean of 46 percent. Neurologic side effects of abnormal involuntary movements, falls, and oscillations in performance were not improved over levodopa used alone. The combined therapy is to be preferred over the use of levodopa alone in the symptomatic management of Parkinson's disease.
左旋多巴与外周多巴脱羧酶抑制剂苄丝肼（Ro 4-4602）联合用药，在132例帕金森病患者中进行了为期75个月的观察研究。这种联合治疗方法无生物毒性，95%的患者耐受性良好，且疗效显著：72%的患者在功能活动量表上改善超过50%，整个组在客观指标上平均改善46%。与单独使用左旋多巴相比，异常不自主运动、跌倒和运动波动等神经方面的副作用并无改善。在帕金森病的症状管理中，联合治疗比单独使用左旋多巴更可取。
